CCL20 secreted by KRT15(high) tumor Cells promotes tertiary lymphoid structure formation and enhances anti-PD-1 therapy response in HPV(+)HNSCC

由KRT15(高表达)肿瘤细胞分泌的CCL20促进三级淋巴结构形成,并增强HPV(+)头颈部鳞状细胞癌(HNSCC)对PD-1抑制剂的治疗反应。

阅读:3

Abstract

Tertiary lymphoid structures (TLS) are associated with an improved response to Immune checkpoint therapy (ICT) in head and neck squamous cell carcinoma (HNSCC). Human papillomavirus (HPV) infection constitutes a high-risk factor for HNSCC carcinogenesis. However, its role in TLS formation has yet to be elucidated. Herein, immunohistochemical (IHC) analysis from 59 HNSCC patients revealed a higher prevalence of mature TLS in HPV-positive (HPV(+)) HNSCC compared to HPV-negative (HPV(-)) cases. Furthermore, integrated analysis of single-cell RNA sequencing, spatial transcriptomics, and RNA-seq data indicated that TLS-positive tumors were characterized by an expanded population of KRT15(high) tumor cells in HNSCC. IHC and cytological experiments confirmed upregulation of KRT15 in HPV(+)HNSCC tumor cells, which also showed high expression of cancer stem cell marker genes. These KRT15(high) stem-like tumor cells specifically secreted CCL20, which was related to the infiltration of TLS-associated immune cells in HPV(+)HNSCC. Murine models confirmed that CCL20 treatment promoted TLS formation and enhanced the efficacy of anti-PD-1 therapy. Multiplex immunofluorescence showed that TLS provided specialized microenvironments that supported the proliferation of CD39(+)PD-1(+)CD8(+)T cells. Collectively, our findings proposed that CCL20 secreted by HPV-infected KRT15(high) tumor cells promoted TLS formation, thereby enhancing anti-PD-1 therapy responses in HPV(+)HNSCC. This study provides mechanistic insights into HPV-mediated TLS development and supports precision immunotherapeutic strategies for HNSCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。